Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

124.09USD
4:00pm EDT
Change (% chg)

$-0.34 (-0.27%)
Prev Close
$124.43
Open
$124.28
Day's High
$125.05
Day's Low
$123.96
Volume
927,529
Avg. Vol
1,456,930
52-wk High
$127.61
52-wk Low
$94.42

CELG.OQ

Chart for CELG.OQ

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $96,802.37
Shares Outstanding(Mil.): 777.97
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 50.05 49.04 30.15
EPS (TTM): 2.49 -- --
ROI: 7.98 -2.17 13.05
ROE: 31.94 5.20 14.20

BRIEF-Oncolytics Biotech enters collaboration with Myeloma UK and Celgene

* Oncolytics biotech enters into first-in-class collaboration with Myeloma UK and Celgene using Reolysin in combination with Imnovid or Revlimid in patients with Myeloma

Mar 16 2017

BRIEF-Alliqua Biomedical says co and Celgene entered into side letter agreement

* On March 13, 2017, co and Celgene entered into a side letter agreement - sec filing

Mar 15 2017

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

Mar 13 2017

Celgene, whistleblower pursuing mediation in off-label marketing case

Celgene Corp and a whistleblower who brought a lawsuit accusing it of promoting its cancer drugs Revlimid and Thalomid for off-label uses have asked the judge presiding over the case not to issue any substantive rulings for 30 days while they pursue mediation.

Mar 01 2017

BRIEF-Celgene announces retirement of president and COO Jacqualyn Fouse

* Celgene announces retirement of president and Chief Operating Officer, Jacqualyn Fouse, Ph.D. And promotion of Scott Smith to president and chief operating officer Source text for Eikon: Further company coverage:

Feb 23 2017

BRIEF-FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT

* FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT)

Feb 22 2017

BRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

* Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

Feb 17 2017

Celgene to pay $198.5 million to settle drug patent licensing case

Biopharmaceutical company Celgene Corp has agreed to pay $198.5 million to resolve a lawsuit accusing it of failing to pay royalties on patents for two drugs subject to a licensing agreement.

Feb 16 2017

BRIEF-Soros Fund Management takes in Facebook, ups in T Mobile and Alphabet

* Soros Fund Management takes share stake in facebook inc of 353,686 shares

Feb 14 2017

BRIEF-Neximmune acquired by group of investors led by former Celgene and Medtronic CEOs

* Acquired by a consortium of private investors led by former Celgene and Medtronic ceos Source text for Eikon:

Feb 14 2017

More From Around the Web

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,139 --
Eisai Co., Ltd (4523.T) ¥5,959 --
Johnson & Johnson (JNJ.N) $124.92 -0.74
Novartis AG (NOVN.S) CHF74.50 +0.75
Pfizer Inc. (PFE.N) $34.33 +0.17
Roche Holding Ltd. (ROG.S) CHF255.40 +2.30
Roche Holding Ltd. (RO.S) CHF254.75 +1.75
Merck & Co., Inc. (MRK.N) $63.64 +0.30
Sanofi SA (SASY.PA) €84.51 +0.57
AstraZeneca plc (AZN.L) 4,954.50 -5.50

Earnings vs. Estimates